# Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Canonical URL: https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-poster-presentation-at-the-american-association-for-cancer-research-aacr-annual-meeting-2026
Ticker: CNTX
Company: Context Therapeutics
Source: Context Therapeutics
Published: 2026-03-19 11:30 EST
Original Source URL: https://ir.contexttherapeutics.com
## Summary

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American

## Article Body
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American
## Recent Company News
- 2026-05-27 11:30 EST — [Context Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Context Therapeutics
- 2026-05-18 10:45 EST — [Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202](https://biopharmsignal.com/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202) — Source: Context Therapeutics
- 2026-05-06 20:18 EST — [Context Therapeutics Reports First Quarter 2026 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-first-quarter-2026-operating-and-financial-results) — Source: Context Therapeutics
- 2026-04-02 11:30 EST — [Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-ctim-76-receives-fda-fast-track-designation-for-the-treatment-of-platinum-resistant-ovarian-cancer) — Source: Context Therapeutics
- 2026-03-23 20:16 EST — [Context Therapeutics Reports Full Year 2025 Operating and Financial Results](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-full-year-2025-operating-and-financial-results) — Source: Context Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)